论文部分内容阅读
目的研究孟鲁司特联合布地奈德治疗哮喘患儿的临床疗效。方法选取2013年5月—2015年5月儿科收集治疗的100例哮喘患儿作为研究对象,按照随机奇偶数字法分为治疗组和对照组,各50例;对照组患儿行布地奈德雾化治疗,治疗组患儿加用孟鲁司特治疗;分析比较两组治疗情况、肺功能改善、不良反应等。结果两组肺功能比较,组内治疗后优于治疗前,差异显著(P<0.05);治疗后治疗组高于对照组,差异显著(P<0.05);治疗组憋醒天数、咳嗽评分、哮喘评分均短于对照组,差异显著(P<0.05);不良反应率比较:治疗组14.0%低于对照组30.0%,差异显著(P<0.05)。结论孟鲁司特联合布地奈德对哮喘患儿的治疗可明显改善患儿肺功能,控制哮喘症状,且无严重不良反应,具有较高的临床应用价值。
Objective To study the clinical efficacy of montelukast combined with budesonide in the treatment of children with asthma. Methods A total of 100 asthmatic children with pediatric collection and treatment from May 2013 to May 2015 were selected as study subjects and divided into treatment group and control group according to random parity method. In the treatment group, children in the treatment group were treated with montelukast. The treatment and improvement of lung function and adverse reactions were analyzed and compared. Results The pulmonary function of the two groups was better than that before treatment after treatment (P <0.05), and the difference was significant (P <0.05) between the treatment group and the control group. The number of days of awakening, cough score, Asthma score were shorter than the control group, the difference was significant (P <0.05); adverse reaction rate: the treatment group 14.0% lower than the control group 30.0%, the difference was significant (P <0.05). Conclusion The treatment of asthmatic children with montelukast combined with budesonide can significantly improve children’s lung function, control asthma symptoms, and no serious adverse reactions, and has a high clinical value.